Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

A Corrigendum to this article was published on 01 May 2006

Abstract

We have previously shown that a single portal vein infusion of a recombinant adeno-associated viral vector (rAAV) expressing canine Factor IX (F.IX) resulted in long-term expression of therapeutic levels of F.IX in dogs with severe hemophilia B1. We carried out a phase 1/2 dose-escalation clinical study to extend this approach to humans with severe hemophilia B. rAAV-2 vector expressing human F.IX was infused through the hepatic artery into seven subjects. The data show that: (i) vector infusion at doses up to 2 × 1012 vg/kg was not associated with acute or long-lasting toxicity; (ii) therapeutic levels of F.IX were achieved at the highest dose tested; (iii) duration of expression at therapeutic levels was limited to a period of 8 weeks; (iv) a gradual decline in F.IX was accompanied by a transient asymptomatic elevation of liver transaminases that resolved without treatment. Further studies suggested that destruction of transduced hepatocytes by cell-mediated immunity targeting antigens of the AAV capsid caused both the decline in F.IX and the transient transaminitis. We conclude that rAAV-2 vectors can transduce human hepatocytes in vivo to result in therapeutically relevant levels of F.IX, but that future studies in humans may require immunomodulation to achieve long-term expression*.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: F9 expression cassette and results of rAAV-F.IX in subjects E, F and G.
Figure 2: IFN-γ ELISPOT data in subject G.

Similar content being viewed by others

Notes

  1. NOTE:In the version of this article originally published, Pradip Rustagi was inadvertently omitted from the author list; John Rasko should be listed as John E. J. Rasko; the affiliations of John E. J. Rasko and Katherine A. High were incorrect; and the author order was incorrect. The correct list of authors with their affiliations is:

    Catherine S Manno1,2,15, Glenn F Pierce3,15, Valder R Arruda1,2,15, Bertil Glader4,15, Margaret Ragni5, John J E Rasko6, Margareth C Ozelo7, Keith Hoots8, Philip Blatt9, Barbara Konkle10, Michael Dake4, Robin Kaye1,2, Mahmood Razavi4, Albert Zajko10, James Zehnder4, Pradip K Rustagi11, Hiroyuki Nakai4, Amy Chew1,3, Debra Leonard2,12, J Fraser Wright3, Ruth R Lessard3, Jürg M Sommer3, Michael Tigges3, Denise Sabatino1, Alvin Luk3, Haiyan Jiang3, Federico Mingozzi1, Linda Couto3, Hildegund C Ertl1,13, Katherine A High1,2,14 & Mark A Kay4

    1The Children’s Hospital of Philadelphia, Philadelphia and 2University of Pennsylvania School of Medicine, 3615 Civic Center Boulevard, Philadelphia, Pennsylvania, 19104, USA. 3Avigen Inc., 1301 Harbor Bay Parkway, Alameda, California 94502, USA. 4Stanford University School of Medicine, 300 Pasteur Drive, Room G305, Stanford, California 94305-5208, USA. 5University of Pittsburgh Medical Center, Hemophilia Center of Western Pennsylvania, 3636 Boulevard of the Allies, Pittsburgh, Pennsylvania 15213, USA. 6Royal Prince Alfred Hospital, Centenary Institute of Cancer Medicine & Cell Biology, Locked Bag No. 6, Newtown NSW 2042, Australia. 7University of Campinas, State University of Campinas, Caixa Postal 6198, CEP, 13083-970, Campinas-Sao Paolo, Brazil. 8University of Texas Houston Health Science Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. 9Christiana Care, Christiana Hospital, 4755 Ogletown-Stanton Road, Newark, Delaware 19713, USA. 10University of Pennsylvania School of Medicine Presbyterian Hospital, MAB, Suite 103, 39th & Market Street, Philadelphia., Pennsylvania 19104, USA. 11Stanford University, School of Medicine, Department of Hematology, Jane Lathrop Building, 770 Welch Road, Suite 380, Palo Alto, California 94304, USA. 12Weill Medical College of Cornell University, 525 East 68th Street, New York, New York 10012, USA. 13Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania 19104, USA.. 14Howard Hughes Medical Institute, 3615 Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA. 15These authors contributed equally to this work. Correspondence should be addressed to K.A.H. (high@email.chop.edu).

    The error has been corrected in the HTML and PDF versions of the article.

References

  1. Mount, J.D. et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 99, 2670–2676 (2002).

    Article  CAS  Google Scholar 

  2. Ljung, R.C. Can haemophilic arthropathy be prevented? Br. J. Haematol. 101, 215–219 (1998).

    Article  CAS  Google Scholar 

  3. Lofqvist, T., Nilsson, I.M., Berntorp, E. & Pettersson, H. Haemophilia prophylaxis in young patients–a long-term follow-up. J. Intern. Med. 241, 395–400 (1997).

    Article  CAS  Google Scholar 

  4. Snyder, R.O. et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat. Med. 5, 64–70 (1999).

    Article  CAS  Google Scholar 

  5. Wang, L., Nichols, T.C., Read, M.S., Bellinger, D.A. & Verma, I.M. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol. Ther. 1, 154–158 (2000).

    Article  CAS  Google Scholar 

  6. Kay, M.A. et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24, 257–261 (2000).

    Article  CAS  Google Scholar 

  7. Manno, C.S. et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963–2972 (2003).

    Article  CAS  Google Scholar 

  8. Acland, G.M. et al. Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28, 92–95 (2001).

    CAS  PubMed  Google Scholar 

  9. Arruda, V.R. et al. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 105, 3458–3464 (2005).

    Article  CAS  Google Scholar 

  10. Herzog, R.W. et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med. 5, 56–63 (1999).

    Article  CAS  Google Scholar 

  11. Chao, H. et al. Persistent expression of canine factor IX in hemophilia B canines. Gene Ther. 6, 1695–1704 (1999).

    Article  CAS  Google Scholar 

  12. Scallan, C.D. et al. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood 102, 2031–2037 (2003).

    Article  CAS  Google Scholar 

  13. Nathwani, A.C. et al. Self complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood published online 1 December 2005 (10.1182/blood-2005-10-4035).

  14. Nathwani, A.C. et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 100, 1662–1669 (2002).

    Article  CAS  Google Scholar 

  15. Wang, L. et al. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 105, 3079–3086 (2005).

    Article  CAS  Google Scholar 

  16. Miao, C.H. et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol. Ther. 1, 522–532 (2000).

    Article  CAS  Google Scholar 

  17. Le, M. et al. Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. Blood 89, 1254–1259 (1997).

    CAS  PubMed  Google Scholar 

  18. Arruda, V.R. et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol. Ther. 4, 586–592 (2001).

    Article  CAS  Google Scholar 

  19. Couto, L., Parker, A. & Gordon, J.W. Direct exposure of mouse spermatozoa to very high concentrations of a serotype-2 adeno-associated virus gene therapy vector fails to lead to germ cell transduction. Hum. Gene Ther. 15, 287–291 (2004).

    Article  CAS  Google Scholar 

  20. Appay, V. & Rowland-Jones, S.L. Lessons from the study of T-cell differentiation in persistent human virus infection. Semin. Immunol. 16, 205–212 (2004).

    Article  CAS  Google Scholar 

  21. Thomas, C.E., Storm, T.A., Huang, Z. & Kay, M.A. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 78, 3110–3122 (2004).

    Article  CAS  Google Scholar 

  22. Hauck, B., Zhao, W., High, K. & Xiao, W. Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adeno-associated virus transduction. J. Virol. 78, 13678–13686 (2004).

    Article  CAS  Google Scholar 

  23. Kurachi, S., Hitomi, Y., Furukawa, M. & Kurachi, K. Role of intron I in expression of the human factor IX gene. J. Biol. Chem. 270, 5276–5281 (1995).

    Article  CAS  Google Scholar 

  24. Wright, J.F. et al. Indentification of factors that contribute to recombinant AAV2 particle aggregation an methods to prevent its occurrence during vector purification and formulation. Mol. Ther. 12, 171–178 (2005).

    Article  CAS  Google Scholar 

  25. Sommer, J.M. et al. Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol. Ther. 7, 122–128 (2003).

    Article  CAS  Google Scholar 

  26. Kreher, C.R., Dittrich, M.T., Guerkov, R., Boehm, B.O. & Tary-Lehmann, M. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J. Immunol. Methods 278, 79–93 (2003).

    Article  CAS  Google Scholar 

  27. Currier, J.R. et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 260, 157–172 (2002).

    Article  CAS  Google Scholar 

  28. Bedossa, P., Poynard, T. & Group, M.C.S. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24, 289–293 (1996).

    Article  CAS  Google Scholar 

  29. The French METAVIR Cooperative Study Group. Interobserver and intraobserver variation in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20, 15–20 (1994).

Download references

Acknowledgements

This work was supported by US National Institutes of Health grants U01 HL66948 (to M.A.K., K.A.H., C.S.M., B.G.), R01 HL71518 (to C.S.M.), P01 HL064190 (to K.A.H.), K01 DK60580 (to V.R.A.) and by the Howard Hughes Medical Institute. We thank each of the subjects for agreeing to participate in this study. We thank J. Bluestone and C. June for their scientific input. We thank J.W. Sun for assistance, critical reading and bioinformatics support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Katherine A High.

Ethics declarations

Competing interests

Glenn F. Pierce, Hiroyuki Nakai, Amy Chew, J. Fraser Wright, Ruth Lessard, Jürg M. Sommer, Michael Tigges, Alvin Luk, Haiyan Jiang, Linda Couto and Mark A. Kay are employed by or hold equity in Avigen, Inc., which manufactured the clinical-grade vector used in the study.

Supplementary information

Supplementary Fig. 1

T cell epitopes identified by ELISPOT assays (colored and underlined) are highly conserved in serotypes 1-8. (PDF 382 kb)

Supplementary Table 1

Inclusion/exclusion criteria. (PDF 45 kb)

Supplementary Table 2

Vector biodistribution by dose group and body fluid/tissue based on PCR assay for vector sequences. (PDF 67 kb)

Supplementary Table 3

AAV sequences in semen and semen fractions of subject A. (PDF 37 kb)

Supplementary Table 4

ELISA of human FIX antigen in plasma of subject E post infusion of AAV2-hFIX vector. (PDF 29 kb)

Supplementary Table 5

Neutralizing antibody (NAB) titers of AAV as a function of time after vector administration in subjects infused with AAV-F.IX. (PDF 37 kb)

Supplementary Table 6

Evaluation of elevated transaminases in subject E. (PDF 29 kb)

Supplementary Methods (PDF 54 kb)

Supplementary Note (PDF 38 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Manno, C., Pierce, G., Arruda, V. et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12, 342–347 (2006). https://doi.org/10.1038/nm1358

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1358

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing